Are We Underestimating Prehypertension?

Circ_0000284: A risk factor and potential biomarker for prehypertension and hypertension

CircRNAs have been shown to be involved in the development of certain diseases, but their application in prehypertension and hypertension remains unclear. We aimed to explore the potential role of circ_0000284 in revealing the molecular regulatory mechanisms of prehypertension and hypertension. We enrolled a total of 100 patients with normal blood pressure, 100 patients with prehypertension and 100 patients with hypertension. The expression of circ_0000284 among the groups was detected by real-time fluorescence quantitative polymerase chain reaction (qRT‒PCR). Multivariate logistic models were constructed combining conventional risk factors with circ_0000284. A receiver operating characteristic curve (ROC) was used to analyze the diagnostic value of circRNAs in the clinical model. Spearman correlation was used to analyze the correlation of circ_0000284 and the biochemical characteristics of all subjects. The results showed that circ_0000284 was differentially expressed among the normal blood pressure group, prehypertensive group and hypertensive group and showed a significantly upregulated trend in the progression to hypertension (P < 0.05). The ROC curve revealed a high diagnostic ability of circ_0000284 in hypertension in the clinical model (AUC = 0.812). Circ_0000284 also presented a certain ability for early diagnosis of prehypertension (AUC = 0.628). Spearman correlation showed that circ_0000284 was positively correlated with Na and CKMB. Our study suggested that upregulated expression of circ_0000284 was an independent risk factor for prehypertension and hypertension. Circ_0000284 was a potential fingerprint for the early diagnosis of hypertension and distinguished the intermediate stage of hypertension development. Moreover, our study provided new insight into the correlation between circ_0000284 and cardiac injury in the progression to hypertension.

Short-term efficacy of non-pharmacological interventions for global population with elevated blood pressure: A network meta-analysis

Background

This study aims to compare the potential short-term effects of non-pharmacological interventions (NPIs) on prehypertensive people, and provide evidence for intervention models with potential in future community-based management.

Methods

In this Bayesian network meta-analysis, Pubmed, Embase, and Web of science were screened up to 16 October 2021. Prehypertensive patients (systolic blood pressure, SBP 120-139 mmHg/diastolic blood pressure, DBP 80-89 mmHg) with a follow-up period longer than 4 weeks were targeted. Sixteen NPIs were identified during the scope review and categorized into five groups. Reduction in SBP and DBP was selected as outcome variables and the effect sizes were compared using consistency models among interventions and intervention groups. Grade approach was used to assess the certainty of evidence.

Results

Thirty-nine studies with 8,279 participants were included. For SBP, strengthen exercises were the most advantageous intervention group when compared with usual care (mean difference = -6.02 mmHg, 95% CI -8.16 to -3.87), and combination exercise, isometric exercise, and aerobic exercise were the three most effective specific interventions. For DBP, relaxation was the most advantageous intervention group when compared with usual care (mean difference = -4.99 mmHg, 95% CI -7.03 to -2.96), and acupuncture, meditation, and combination exercise were the three most effective specific interventions. No inconsistency was found between indirect and direct evidence. However, heterogeneity was detected in some studies.

Conclusion

NPIs can bring short-term BP reduction benefits for prehypertensive patients, especially exercise and relaxation. NPIs could potentially be included in community-based disease management for prehypertensive population once long-term real-world effectiveness and cost-effectiveness are proven.

Systematic review registration

https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=151518, identifier: CRD42020151518.

Serum uric acid and risk of prehypertension: a dose-response meta-analysis of 17 observational studies of approximately 79 thousand participants

BACKGROUND

Studies examining the association between levels of serum uric acid (SUA) and risk of prehypertension still remained controversial conclusions. Also, a quantitative assessment of the dose-response association between them has not been reported. We aimed to quantitatively evaluate risk of prehypertension with levels of SUA based on observational study.

METHODS

We searched the PubMed, Embase, and Web of Science databases up to December 3, 2019 for relevant studies. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random-effects models. The possible linear or non-linear SUA-prehypertension association was modelled by restricted cubic splines.

RESULTS

We included 17 articles (17 studies) with a total of 79,358 participants and 34,591 cases of prehypertension. Compared with lowest levels of SUA, risk of prehypertension increased 46% (RR 1.46, 95% CI 1.28-1.66) for highest levels of SUA. For per 1 mg/dL increment in levels of SUA, risk of prehypertension increased by 12% (RR 1.12, 95% CI 1.08-1.17). Also, we found evidence of a linear SUA-prehypertension association (P_{non-linearity}=.368).

CONCLUSION

Elevated levels of SUA may be associated with increased risk of prehypertension. Present findings provide the evidence that lowering levels of SUA should be suggested in order to reduce the risk of prehypertension. More longitudinal and intervention studies are needed to clarify the optimal protective levels and whether reducing levels of SUA could prevent or control prehypertension and the progression of prehypertension to hypertension.